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Abstract
Background: Staphylococcal infection of the canine epidermis and hair follicle is amongst the commonest reasons
for antimicrobial prescribing in small animal veterinary practice. Topical therapy with fusidic acid (FA) is an attractive
alternative to systemic therapy based on low minimum inhibitory concentrations (MICs, commonly <0.03 mg/l)
documented in canine pathogenic staphylococci, including strains of MRSA and MRSP (methicillin-resistant
Staphylococcus aureus and S. pseudintermedius). However, permeation of canine skin by FA has not been evaluated
in detail. This study aimed to define the degree and extent of FA permeation in canine skin in vitro from two sites
with different hair follicle density following application of a licensed ophthalmic formulation that shares the same
vehicle as an FA-betamethasone combination product approved for dermal application in dogs. Topical FA
application was modelled using skin held in Franz-type diffusion cells. Concentrations of FA in surface swabs,
receptor fluid, and transverse skin sections of defined anatomical depth were determined using high-performance
liquid chromatography and ultraviolet (HPLC-UV) analysis.
Results: The majority of FA was recovered by surface swabs after 24 h, as expected (mean ± SEM: 76.0 ± 17.0%). FA
was detected within 424/470 (90%) groups of serial sections of transversely cryotomed skin containing follicular
infundibula, but never in 48/48 (100%) groups of sections containing only deeper follicular structures, nor in
receptor fluid, suggesting that FA does not permeate beyond the infundibulum. The FA concentration (mean ±
SEM) in the most superficial 240 μm of skin was 2000 ± 815 μg/g.
Conclusions: Topically applied FA can greatly exceed MICs for canine pathogenic staphylococci at the most
common sites of infection. Topical FA therapy should now be evaluated using available formulations in vivo as an
alternative to systemic therapy for canine superficial bacterial folliculitis.
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Background
Antibiotic resistance is a major threat to global health
and modern medicine [1]. Canine pyoderma caused by
Staphylococcus pseudintermedius is amongst the com-
monest reasons for prescribing antimicrobial drugs in
small animal veterinary practice [2]. Traditionally in ca-
nine practice, surface infections (confined to the inter-
follicular epidermis) are treated topically, whereas super-
ficial infections such as bacterial folliculitis (that extend
to the follicular infundibulum without extension into the
surrounding dermis) are treated with oral antibiotics.
The recent emergence of methicillin-resistant S. pseu-
dintermedius (MRSP) [3] that are routinely resistant to
licensed oral antibiotics has renewed interest in the dir-
ect application of topical antibiotics and antiseptics for
superficial pyoderma [4, 5].
Fusidic acid (FA) is an antibiotic which has a steroid-
like structure, with proven activity in vitro against
coagulase-positive staphylococci including MRSP [6, 7].
The physico-chemical properties of this large, lipophilic
molecule (molecular weight of 517 kDa, octanol/water
partition co-efficient >4, 6 free hydrogen bonding
groups) predict limited diffusivity through stratum cor-
neum and restricted partitioning to the more hydrophilic
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living epidermis, after topical application [8, 9]. These
features correlate with clinical efficacy of licensed FA-
containing topical veterinary products in surface infec-
tions such as canine acute moist [pyotraumatic] derma-
titis [10]. Utility in canine superficial pyoderma,
however, is dependent upon adequate permeation into
hair follicles, but this has received little attention. Stud-
ies of clinical efficacy of topical FA in canine superficial
pyoderma / bacterial folliculitis are lacking [4, 11].
Stuttgen and Bauer established that in sparsely-haired
human skin, FA is limited to the stratum corneum and
epidermis after topical gel application, and does not
penetrate into the deep dermis or subcutaneous fat [12].
By contrast, Degim et al. reported that 1.3% of FA in a
betamethasone-containing gel formulation penetrated
full-thickness haired canine skin in diffusion cell studies
[13]. Skin integrity was not assessed prior to gel applica-
tion, and FA was quantified in only receptor fluid and
not on or within skin itself [13].
In view of these prior conflicting and incomplete data,
we developed an in vitro model of topical FA application
using canine skin held in Franz-type diffusion cells and
high-performance liquid chromatography and ultraviolet
(HPLC-UV) analysis of FA concentrations to define the
degree and extent of drug permeation in skin from sites
with varying hair follicle density. We describe for the
first time how the depth of drug permeation into dermal
layers can be defined by concurrent observation, in rep-
resentative paired transverse histological sections [14,
15], of the variations in hair follicle anatomy that mark
the infundibulum, isthmus and inferior portions of hair
follicles. In addition, conventional analyses of drug re-
covery in receptor fluid and swabs from surface of dosed
skin complemented evaluation of dermal drug concen-
trations. These data were used to inform likely clinical
utility in canine superficial and deep pyoderma.
Methods
HPLC-UV detection of fusidic acid.
Validation
Fusidic acid sodium salt (≥98%, Sigma-Aldrich, Irvine,
UK) was diluted in absolute ethanol to produce standard
(0.5–49 μg/ml) and quality control (0.5, 1.0, 6.5 and
40 μg/ml) solutions (see Additional file 1 for chemicals
used). High Performance Liquid Chromatography –
ultraviolet analysis (HPLC-UV) was performed using an
Ultimate 3000 (Thermo Scientific, Paisley, UK) system
comprising quaternary pump, autosampler, column oven
and diode array detector. The column was from Kinetex
(C18 2.1 mm × 50 mm, 1.7 μm particle size; Phenom-
enex, Macclesfield, UK) held at 35 °C. Mobile phase A
comprised methanol; mobile phase B 0.1 M acetic acid.
Mobile phase A/B was ramped from 30/70 to 78/22 v/v
ratio over 4 min and then held for 5 min. Mobile phase
A/B then returned to 30/70 over 30 s and re-
equilibrated for 7 min. The flow rate was maintained at
0.35 ml/min. The retention time of FA was 9.1 min, with
UV detection at 240 nm.
Samples were analysed using a validated method de-
veloped at the University of Hertfordshire in accordance
with OECD guidelines for studies of skin absorption in
vitro [16]. Injection volume was 2 μl. The linear dynamic
range for FA, based on peak areas with 1/x2 weighted re-
gression was 1.24–249 ng on column (R2 = 0.9998), with
limit of detection (LOD) of 0.50 ng on column (signal/
noise = 3). System precision, determined using replicate
injections (n = 10) at 1.24 and 187 ng on column, was
6.6 and 0.76%, respectively. Receptor fluid, cotton wool
swab and canine cryosection extracts (from 8 different
animals) demonstrated no matrix interference at the re-
tention time of FA. The calibration range was 0.5–
49 μg/ml. Satisfactory intra and inter-run accuracy (87–
107%) and precision (±15%) was obtained at low (1.0 μg/
ml), mid (6.5 μg/ml) and high (40 μg/ml) concentrations
of the calibration curve and at the limit of quantification
(LOQ, 0.5 μg/ml). Extraction efficacies of FA from
spiked canine skin cryosections (at low, mid, and high
QC levels, 8 replicates of each) using ethanol con-
firmed recoveries to be 98.7–101.3%. Stabilities of
spiking solutions and spiked matrices were shown to
be at least 2 weeks when refrigerated. All experimen-
tal samples were analysed within 14 days of refriger-
ated storage.
Analysis of samples
Standard solutions covering the calibration range were
run at the start of each batch with low, mid and high
QCs bracketing no more than 15 test samples. Batch
sample data were accepted when the accuracy and preci-
sion of these met validation criteria. In order to obtain
concentrations of FA found in skin samples, the amount
of FA found in the skin was adjusted for the sample
weight from which the sample was obtained.
Canine skin collection
Full thickness canine skin was obtained from healthy
Beagle dogs (three male, three female, aged 6–12 months,
8–14 kg) immediately after euthanasia for reasons unre-
lated to this study (approved by the Royal Veterinary
College’s Clinical Research Ethical Review Board 2016
1651–2-R). Hair was clipped (Moser Arco 1854, Wahl,
Sterling, IL, USA) to within 3 mm of skin surface taking
care not to damage skin integrity, and skin was then ex-
cised from the dorsum and groin of each dog, immedi-
ately wrapped in tin foil and chilled by frozen ice blocks
prior to storage at -20 °C within 6 h of collection. Har-
vested skin was used within 5 months [17].
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Skin measurements
Thickness of whole skin specimens
The thickness of the centre of each 3 × 3 cm portion of
skin was measured using callipers immediately before
assembly into the diffusion cells, as described below.
Thickness of stratum corneum
Vertical cryosections through full thickness skin were
prepared from undosed skin from each treatment group
(undamaged, shampoo-treated and tape-stripped skin)
for both dorsum and groin for all six animals (total n =
36). Eight cryosections were taken from each piece of
skin, sectioning both from panniculus to epidermis (n =
4) and from epidermis to panniculus (n = 4), and stained
with haematoxylin and eosin. Thickness of stratum cor-
neum was measured at three points per section where
stratum corneum was at its most compact / intact and
not obviously folded [18] using a light microscope (×40
magnification) and Image-Pro Plus v5.0.1.11 software
(Media Cybernetics, Duxford, UK).
Hair follicle density
Hair follicle density (compound follicles per mm2) and
infundibular area (as a percentage of skin area) at the
level of the common infundibulum were compared in
replicate control untreated dorsal (n = 6) and groin (n =
6) skin samples by microscopy of transverse haematoxy-
lin and eosin-stained paraffin sections of skin from one
male and one female Beagle dog. The hair follicle count
and area were measured at three randomly selected
areas per section using microscope settings and software
as for stratum corneum measurements described above.
Electrical resistance
Electrical resistance between saline treated epidermal
skin surface and receptor fluid was used to assess skin
barrier integrity in each assembled diffusion cell using
an ohmmeter (Iso-Tech LCR-821 Meter, Iso-Tech,
Southport, UK) [19].
Diffusion cell experiment
Four dermal absorption experiments with full thickness
canine skin were conducted using a 10 mg/g FA suspen-
sion (Isathal®, Dechra Veterinary Products (DVP), Shrop-
shire, UK) which contains the same vehicle as a licensed
topical skin product for dogs (Isaderm®, DVP). Dorsal and
groin skin sourced from six animals (three dogs per ex-
periment) was defrosted and defatted by blunt dissection
before division into three evenly sized pieces (70 cm2),
one for each treatment group and assembled into diffu-
sion cells containing receptor fluid within 3 h. For each
experiment, 21 static Franz diffusion cells (Permgear Inc.
Hellertown, PA USA) were assembled with portions of ei-
ther dorsal or groin skin (3 cm × 3 cm) which had either
been left untreated (n = 6), repeatedly tape-stripped (n = 6)
to mimic damage to the stratum corneum, or shampooed
with a 2% chlorhexidine and 2% miconazole shampoo
(Malaseb®, DVP) to mimic clinical use (n = 6). One diffu-
sion cell containing untreated skin from each animal was
assembled but left undosed (negative controls). Skin allo-
cated to be tape-stripped was quickly [20] and repeatedly
(n = 30) [20] stripped with D-Squame discs (22 mm;
Cuderm, Dallas, TX, USA) prior to assembly into the cells.
A uniform pressure was applied to each disc for 2 s using
a 225 g/cm2 applicator before disc removal with forceps.
The epidermal surface of relevant portions of excised skin
(approximately 70 cm2) were moistened and shampooed
(0.02 ml/cm2) for 2 min by hand, then left for 10 min, as
per label instructions for clinical use, prior to rinsing with
water (2 × 5 ml). Treated skin was blotted dry with paper
towels and cut into pieces for assembly into the cells.
Each piece of skin was placed between a glass receptor
chamber, containing measured volumes (approximately
14 ml) of ethanol / pH 5.0 phosphate buffered saline,
25/75 v/v [13], and a magnetic stirrer, and glass donor
chamber and secured by pinch clamp, exposing
1.77 cm2. Diffusion cells were randomly assigned posi-
tions in stirrer blocks and plumbed into a heated water
circulator system in order to maintain a constant skin
surface temperature of 32.0 ± 1.0 °C confirmed by infra-
red camera (P620, FLIR, West Malling UK). Skin barrier
integrity was established in each cell by measurement of
electrical resistance as described above.
After equilibration overnight, 18 of the 21 assembled
cells were dosed with 100 μl of the FA suspension using
a calibrated positive displacement pipette. Saline (0.9%,
100 μl) was added by pipette to all cells in order to li-
quefy the gel [13]. A glass rod was used to gently spread
the gel across the entire exposed surface of skin. The
total amount of FA applied to each cell was determined
by weighing the filled and emptied pipette tip and the
glass rod before and after use. The donor chambers were
then promptly occluded using plastic paraffin film.
Receptor fluid samples (250 μl) were collected from
each cell before (pre-dose) and at 12 and 24 h after dos-
ing, with replacement of equal volumes of fresh receptor
fluid at each time point. Additional sampling intervals
were deemed unnecessary in anticipation of negligible
penetration into the receptor fluid. After 24 h, the donor
chamber was removed and the surface skin and inside of
the donor chamber were both swabbed with cotton
wool. Swabs were transferred to glass vials and soaked in
ethanol (10 ml) for a minimum of 24 h at 4 °C to extract
the FA. Aliquots of the swab extracts and receptor fluid
samples were transferred to autosampler vials (2 ml) and
crimped capped. Skin specimens were gently removed
from the receptor chamber using forceps, taking care
not to touch the exposed area of skin, and were stored
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in foil at −70 °C prior to cryosectioning (to minimise
drug lability in the skin).
FA concentrations in ethanolic swab extracts and re-
ceptor fluid samples were determined by direct injection
of aliquots, transferred to autosampler vials, using the
HPLC-UV method described above.
Skin cryosectioning
OCT-embedded frozen specimens of skin were cryosec-
tioned transversely starting from the deep dermis pro-
ceeding towards epidermis in groups of seven sections,
to avoid cross contamination of sections with the blade.
Each group comprised a) five sequential 20 μm sections
that were placed in individual glass vials and extracted
in ethanol (5 ml) for 24 h, for subsequent FA HPLC-
analysis, and b) a further two 10 μm sections which were
mounted on Polysine™ slides (ThermoFisher Scientific,
Paisley, UK) prior to staining with haematoxylin and
eosin. The stained slides were examined by light micro-
scopical observation of hair follicle anatomy and pres-
ence of other skin structures by a blinded assessor (RB)
to determine the anatomical depth within the skin (Fig-
ure 1). As the highest proportion of hair follicle infun-
dibula were present in the uppermost two vials
(equivalent to a depth of approximately 240 μm) these
were selected for determination of the maximum FA
concentration achievable in the superficial skin layers in
these experiments.
Statistical analyses
Statistical analyses utilised IBM SPSS Statistics Package
21 (IBM, Portsmouth, UK) with P values of ≤0.05 con-
sidered significant. Normality was assessed through
Shapiro-Wilk test prior to use of either the Kruskal-
Wallis test with Dunn’s post-hoc test, or one-way
ANOVA with Bonferroni post-hoc correction as appro-
priate. Chi-squared tests evaluate contingency table data.
Results
FA recovery
The amount of FA applied to canine skin in each diffusion
cell ranged from 762 to 1087 μg (mean ± SEM 946 ± 9 μg).
All QCs and standards running alongside samples met
validation criteria. FA was never detected in any sample
from un-dosed control cells, nor detected within quantifi-
able limits in any receptor fluid sample 24 h after applica-
tion (Table 1). HPLC-UV analyses indicated that total FA
recovery was 90.2 ± 9.0% (range 65–107%) after 24 h; no
significant difference was found between skin sites or
treatment groups (Table 1). From skin surface swabs,
overall recovery of FA was 76.0 ± 17.7% independent of
skin site or treatment group. A significantly (P = 0.002)
a
d c b
Fig. 1 Composite image of the histology of the canine compound hair follicle. a Traditional vertical section through the long axis of a compound
follicle from epidermis (right) to panniculus adiposus (left). Lines indicate planes of section for corresponding transverse images that define depth
of section. b Transverse section at common infundibulum: follicle is lined by stratified squamous keratinising epithelium that recapitulates that of
the interfollicular epidermis and contains multiple naked hair fibres. c Transverse section at isthmus: compound follicle comprises a cranial
primary hair and a group of (commonly 14–18) secondary hair follicles; each hair shaft is surrounded by root sheaths whose anatomy varies with
stage of hair growth. d Transverse section at inferior portion of follicles: presence indicates anagen phase represented by hair fibre surrounded by
inner root sheath and glycogen-rich outer root sheath
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higher percentage of the applied dose was found within
cryosections from the dorsum (17.7 ± 2.4%) in comparison
to the groin (10.7 ± 1.0%; Figure 2).
No significant inter-dog variability in FA distribution was
seen between skin from the six donor dogs within skin
group (undamaged, shampooed or tape-stripped) or site
(Additional file 2).
FA was detected in 80% of vials (376 of 470 vials, equiva-
lent to 72.6% of all 518 vials; Table 2) containing cryo-
sections where follicular infundibula or more superficial
structures (surface hairs, living epidermis, keratin and free
hairs) were observed in representative (paired) histological
specimens. FA was never detected in the absence of these
structures, i.e. in sections containing only isthmi, inferior
portions of the hair follicle or subcutaneous fat (n = 48 vials;
Table 2; P < 0.0005, Chi-squared test).
A mean (± SEM) FA concentration of 395.4 ± 30.9 μg/
g was found in each treated portion of skin 24 h after
topical application (Table 3). No significant differences
(P > 0.05) were seen between the concentrations
achieved in any site or treatment group. The concentra-
tion of FA (mean ± SEM) in the uppermost (from epider-
mal aspect) two vials of cryosections of each skin
specimen (approximately 240 μm) was 2000 ± 815 μg/g.
Skin measurements
Thickness of stratum corneum and whole skin specimens
Dorsal skin thickness (1.1 ± 0.0 cm; range 0.9–
1.4 cm) exceeded (P < 0.0005) that of groin skin
(0.8 ± 0.0 cm; range 0.5–1.1 cm), but overall thick-
ness did not vary between undamaged, tape-
stripped or shampooed skin obtained from either
site. Stratum corneum thickness showed a similar
relationship (dorsum 14.0 ± 2.0 μm; groin 12.0 ±
1.6 μm; P < 0.0005). A non-significant reduction (P
= 0.105) in stratum corneum thickness was seen in
the tape-stripped groin skin compared to the un-
damaged skin (undamaged 12.6 ± 1.9 μm, tape-
stripped 11.7 ± 1.1 μm); shampooing had no mea-
sureable effect. Sectioning from either dermal or
epidermal aspects did not affect stratum corneum
thickness measurements (Additional file 3).
Hair follicle density
The hair follicle density of dorsal skin (mean ± SEM, 5.8
± 0.2 compound follicles/mm2) exceeded (P = 0.004) that
of groin skin (2.2 ± 0.6 compound follicles/mm2), with a
greater percentage of the total sectioned area of skin
containing follicular infundibula (dorsum 19.8 ± 1.8%,
groin 6.7 ± 1.6%; P = 0.004).
Table 1 Mean (±SEM) individual and combined percentage recoveries of FA
Measurement (%) Site Treatment Group
Undamaged Shampooed Tape-stripped
Site of FA recovery Total drug Dorsum 87.2 ± 6.8 93.0 ± 6.7 92.9 ± 3.6
Groin 89.2 ± 5.4 89.2 ± 7.8 89.9 ± 6.0
Surface swab Dorsum 60.4 ± 15.8 80.5 ± 10.0 79.2 ± 6.0
Groin 77.2 ± 5.9 78.5 ± 12.0 80.4 ± 6.4
Skin cryosections Dorsum 26.9 ± 10.2 12.6 ± 4.0 13.7 ± 2.7
Groin 12.0 ± 3.3 10.7 ± 4.5 9.4 ± 3.6
Receptor fluid Dorsum 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Groin 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
FA: fusidic acid. Mean (±SEM) individual and combined percentage recoveries of FA from in vitro diffusion cells containing dorsal or groin skin from healthy
Beagle dogs (n = 6) after topical application of a 10 mg/g FA suspension (Isathal®) for 24 h. Skin samples were undamaged, shampooed or tape-stripped (n = 6 per
group) prior to dosing. After exposure, the skin was swabbed prior to transverse cryosectioning and swabs, skin samples and receptor fluid analysed for
FA content
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FA: fusidic acid.  * denotes a significant difference 
between recovery of FA from skin (P = 0.002)
*
Fig. 2 Individual / combined percentage recoveries of FA
(mean ± SEM) in skin and swab following 24 h topical application of a
10 mg/g carbomer gel formulation of FA to dorsal and groin skin from
healthy Beagle dogs
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Electrical resistance
Barrier integrity testing prior to analysis demonstrated
that electrical resistance was comparable (P = 0.452) be-
tween the dorsum and groin skin (dorsum mean ± SEM
= 3.71 ± 0.19 kΩ, groin = 3.46 ± 0.16 kΩ).
Discussion
The combination of transverse histological sectioning and
HPLC-UV assessment of FA concentrations in serial sec-
tions was pivotal in ascertaining in detail the depth of FA
permeation through canine skin. Coupled with the more
conventional processes of drug recovery in post-treatment
skin, surface swab and receptor fluid samples, these data
confirmed FA permeation to the level of the follicular in-
fundibulum and thus, the presence of drug at the level of
infection in canine superficial bacterial folliculitis follow-
ing topical application. Whilst formulation with different
vehicles commonly influences skin permeation, we used a
commercially available ophthalmological product that
contains the same vehicle as a licensed steroid-containing
topical skin product for dogs (Isaderm®, DVP) to maximise
the clinical relevance of the results of our in vitro study to
veterinary practitioners.
This first report of the proportion of FA remaining on
canine skin surface after application in vitro (76.0 ±
17.7% at 24 h) was remarkably similar to the 80% figure
reported in an analogous study of human skin [12]. The
higher hair follicle density dorsally likely accounts for
the increased amounts of FA present within skin from
this site when compared with groin, particularly since
the presence of drug in skin sections was significantly
associated with histological observation of infundibulae
and other superficial structures.
The failure to detect FA in receptor fluid in this canine
study was in accordance with a previous in vitro penetra-
tion study of human skin [12], and not un-expected from
the physicochemical properties of the molecule [8, 9]. The
limit of detection of this HPLC method was well below the
predicted concentration of FA in receptor fluid had we
reproduced the 1.3% bioavailability described by Degim et
al [13]. The full thickness penetration of FA reported in that
study might reflect technical or procedural differences such
as apparent absence of barrier integrity testing prior to dos-
ing; [13] ensuring that the epidermal barrier layer maintains
its integrity is an essential factor to the successful perform-
ance of diffusion cell experiments [16]. In this study, elec-
trical resistance was used for barrier integrity testing, but
this does not appear to have been described previously for
dogs. Values obtained here fell between those reported for
rat (3 kΩ) and pig (4 kΩ) skin [19], in parallel with relative
stratum corneum thickness in these species (rat 6.0–
13.3 μm<dog 9.4–15.1 μm<pig 13.1–18.1 μm) [21]. Com-
parable electrical resistance and thus barrier integrity in un-
damaged, shampooed and tape-stripped skin correlated
with the equivalent FA penetration across the three groups.
Values reported here should be of use for future skin integ-
rity testing for canine in vitro diffusion experiments.
Our model indicates that topical therapy with FA in
canine skin is likely to achieve concentrations that mark-
edly exceed MICs of staphylococcal strains deemed both
‘susceptible’ and ‘resistant’ using existing interpretative
criteria. By extrapolating the mean FA concentration
achieved in the top 240 μm of skin (2000 ± 815 μg/g)
using a skin density value of 1.09 [22], the overall con-
centration of FA in this region can be estimated as 2180
± 634 mg/l. This markedly exceeds previously reported
MIC90 of both methicillin-resistant and susceptible S.
aureus and S. pseudintermedius [6, 23], and EUCAST
systemic therapy breakpoint for ‘resistance’ (1 mg/l) [24]
and compares favourably with MIC100 values for FA-
resistant MRSA (1024 mg/l) [7]. Development of inter-
pretive criteria for topical rather than just systemic use
of antimicrobial therapy is urgently required.
The stratum corneum thickness of undamaged canine
skin in this study was closely comparable to those of
previous reports [21, 25]. Tape-strip removal of stratum
Table 2 Comparison between presence of infundibular and more superficial structures and presence of FA
Vials with FA detected
n (%)
Vials without FA
n (%)
Infundibulae or surface structures on sections 376 (72.6) 94 (18.1)
No infundibulae or surface structures on sections 0 (0.0) 48 (9.3)
FA: fusidic acid; P < 0.0005, Chi-squared test. Topical application of a 10 mg/g FA suspension (Isathal®) for 24 h to dorsal or groin skin from healthy Beagle dogs
(n = 6) held in diffusion cells; a comparison between the presence of infundibular and more superficial structures (surface hairs, interfollicular epidermis, keratin
and free hairs) versus deeper structures (isthmi,inferior portions, subcutaneous fat) on analysis of histological specimens and the presence of FA in the corresponding
vials of cryosections (vials, n = 518;) when assayed by HPLC-UV
Table 3 Mean (± SEM) concentration of FA measured in
transverse cryosections
FA concentration
(mean μg/g)
Treatment Group
Undamaged
(n = 6)
Shampooed
(n = 6)
Tape-stripped
(n = 6)
Site Dorsum 617.5 ± 135.9 345.0 ± 46.0 346.4 ± 35.4
Groin 392.3 ± 51.8 298.8 ± 47.9 372.4 ± 69.0
Mean (± SEM) concentration of FA measured in transverse cryosections
obtained from full thickness dorsum or groin skin from healthy Beagle dogs
(n = 6) after topical application of a 10 mg/g FA suspension (Isathal®) for 24 h
in four diffusion cell experiments. Skin samples were undamaged, shampooed
or tape-stripped (n = 6 per group) prior to dosing. After exposure, the skin was
swabbed prior to transverse cryosectioning. No significant differences were
seen between the concentrations achieved in any site or treatment group
(ANOVA, P > 0.05)
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corneum cells and lipid is commonly used to degrade the
barrier and enhance drug permeability, although post-
stripping measurements of thickness in cryosections
(which best preserve stratum corneum architecture in
haired skin) [21, 26] are very rarely reported [27–29]. We
speculate that the failure of tape stripping to significantly
reduce canine interfollicular stratum corneum thickness
reflects the combined effects of a dense mat of short stub-
bly hairs reducing D-squame tape access to the interfolli-
cular epidermis (close clipping was avoided to prevent
stratum corneum disruption) [29], uneven skin surface
[30], thicker corneum at follicular ostia [31], and or prefer-
ential removal of loose corneocytes that may be lost or
otherwise not included in measurements of residual com-
pact layers. Further studies that optimise parameters, such
as applicator pressures, numbers of repeat strips and clip-
ping methods [20] for the thin but compact corneal layers
of canine haired skin, are indicated.
Conclusions
These data suggest that topical FA should be useful in the
treatment of canine surface and superficial pyoderma (intact
follicles) caused by bacteria susceptible to fusidic acid, in
countries where it is available, but not deep pyoderma (where
infection extends to surrounding dermis). Clinical studies are
now required to confirm this. Similar studies should now be
performed for other topically applied antibiotics to inform
evidence-based antibiotic treatment guidelines. Although
prevalence of antimicrobial resistance should be monitored
prospectively, FA provides an opportunity for topical anti-
biotic therapy in the treatment of staphylococcal folliculitis in
dogs and an option to reduce selection pressure for anti-
microbial resistance on these zoonotic canine pathogens
from conventional systemic antibiotic use.
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